Cytokinetics Stock Analysis

CYTK -  USA Stock  

USD 29.36  0.30  1.03%

The recent surge in Cytokinetics short term price appreciation could raise concerns from traders as the firm it trading at a share price of 29.36 on 455,100 in volume. The company directors and management have successfully maneuvered the firm at convenient times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.04. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cytokinetics partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Cytokinetics stock analysis report makes it easy to digest most publicly released information about Cytokinetics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cytokinetics Stock analysis module also helps to analyze the Cytokinetics price relationship with some important fundamental indicators such as market cap and management efficiency.

Cytokinetics Stock Analysis Notes

About 109.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.0. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 184 people. For more info on Cytokinetics please contact Robert Blum at 650 624-3000 or go to www.cytokinetics.com.

Cytokinetics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cytokinetics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytokinetics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cytokinetics has very high historical volatility over the last 90 days
Cytokinetics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 58.55 M. Net Loss for the year was (134.99 M) with loss before overhead, payroll, taxes, and interest of (41.12 M).
Cytokinetics has a poor financial position based on the latest SEC disclosures
Latest headline from marketingsentinel.com: Cytokinetics Incorporated Is Currently -8.09 percent Below Its 52-Week High, But Upside Potential Is Still There. - Marketing Sentinel

Cytokinetics Upcoming and Recent Events

Earnings reports are used by Cytokinetics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytokinetics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Cytokinetics Largest EPS Surprises

Earnings surprises can significantly impact Cytokinetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-07-29
2015-06-30-0.23-0.27-0.0417 
2017-02-16
2016-12-310.210.16-0.0523 
2019-08-08
2019-06-30-0.496-0.56-0.06412 
View All Earnings Estimates

Cytokinetics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cytokinetics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cytokinetics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cytokinetics specific information freely available to individual and institutional investors to make a timely investment decision.
23rd of July 2021
Financial Statements and Exhibits. Other Events
View
21st of July 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
19th of July 2021
Financial Statements and Exhibits. Other Events
View
12th of July 2021
Unclassified Corporate Event
View
1st of July 2021
Financial Statements and Exhibits. Other Events
View
30th of June 2021
Other Events
View
15th of June 2021
Other Events
View
1st of June 2021
Financial Statements and Exhibits. Other Events
View

Cytokinetics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytokinetics's market, we take the total number of its shares issued and multiply it by Cytokinetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Cytokinetics Profitablity

Cytokinetics' profitability indicators refer to fundamental financial ratios that showcase Cytokinetics' ability to generate income relative to its revenue or operating costs. If, let's say, Cytokinetics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cytokinetics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cytokinetics' profitability requires more research than a typical breakdown of Cytokinetics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (230.55) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (177.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.78.
Last ReportedProjected for 2021
Return on Investment(51.14) (55.17) 
Return on Average Assets(0.34) (0.37) 
Return on Average Equity(3.66) (3.76) 
Return on Invested Capital(0.29) (0.31) 
Return on Sales(1.99) (2.15) 

Management Efficiency

The entity has return on total asset (ROA) of (15.62) % which means that it has lost $15.62 on every $100 spent on asset. This is way below average. Cytokinetics management efficiency ratios could be used to measure how well cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -55.17. The current Return on Average Assets is estimated to decrease to -0.37. Cytokinetics Total Liabilities is increasing as compared to previous years. The last year's value of Total Liabilities was reported at 420.42 Million. The current Liabilities Non Current is estimated to increase to about 419.9 M, while Current Liabilities is projected to decrease to under 29.4 M.
Last ReportedProjected for 2021
Book Value per Share 1.76  1.98 
Enterprise Value over EBIT(13.00) (13.34) 
Enterprise Value over EBITDA(12.88) (13.22) 
Price to Book Value 12.97  14.00 
Tangible Assets Book Value per Share 8.27  7.15 
Enterprise Value1.4 B1.5 B
Tangible Asset Value533.8 M575.9 M

Technical Drivers

As of the 30th of July, Cytokinetics shows the Mean Deviation of 3.07, risk adjusted performance of 0.0446, and Downside Deviation of 3.15. Cytokinetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Cytokinetics, which can be compared to its rivals. Please confirm Cytokinetics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Cytokinetics is priced correctly, providing market reflects its regular price of 29.36 per share. Given that Cytokinetics has jensen alpha of 0.3518, we suggest you to validate Cytokinetics's prevailing market performance to make sure the company can sustain itself at a future point.

Cytokinetics Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. The Mid-point over period is an average of Cytokinetics highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Cytokinetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Blum six days ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3
Sandford Smith over a week ago via Macroaxis 
Exercise or conversion by Sandford Smith of 5000 shares of Cytokinetics subject to Rule 16b-3
Robert Califf over two weeks ago via Macroaxis 
Acquisition by Robert Califf of tradable shares of Cytokinetics subject to Rule 16b-3
Robert Califf over three weeks ago via Macroaxis 
Acquisition by Robert Califf of 238 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over a month ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over a month ago via Macroaxis 
Sale by Fady Malik of 2000 shares of Cytokinetics
Robert Blum over a month ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two months ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3
Sandford Smith over two months ago via Macroaxis 
Exercise or conversion by Sandford Smith of 3207 shares of Cytokinetics subject to Rule 16b-3
Bhanji Muna over two months ago via Macroaxis 
Acquisition by Bhanji Muna of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two months ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over three months ago via Macroaxis 
Exercise or conversion by Robert Blum of 5000 shares of Cytokinetics subject to Rule 16b-3

Cytokinetics Predictive Daily Indicators

Cytokinetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cytokinetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cytokinetics Forecast Models

Cytokinetics time-series forecasting models is one of many Cytokinetics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytokinetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cytokinetics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytokinetics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytokinetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cytokinetics. By using and applying Cytokinetics Stock analysis, traders can create a robust methodology for identifying Cytokinetics entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin 15.81  17.06 
EBITDA Margin(1.96) (2.12) 
Gross Margin 0.90  0.89 
Profit Margin(2.28) (2.46) 
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 184 people.

Current Cytokinetics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cytokinetics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cytokinetics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
46.25Buy8Odds
Cytokinetics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cytokinetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cytokinetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cytokinetics, talking to its executives and customers, or listening to Cytokinetics conference calls.
Cytokinetics Analyst Advice Details

Cytokinetics Stock Analysis Indicators

Cytokinetics stock analysis indicators help investors evaluate how Cytokinetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cytokinetics shares will generate the highest return on investment. By understating and applying Cytokinetics stock analysis, traders can identify Cytokinetics position entry and exit signals to maximize returns.
Quick Ratio11.97
Fifty Two Week Low14.71
Revenue Growth71.20%
Shares Short Prior Month9.39M
Average Daily Volume Last 10 Day11.57M
Average Daily Volume In Three Month1.79M
Shares Percent Shares Out12.66%
Gross Margins-82.36%
Short Percent Of Float15.33%
Forward Price Earnings-9.40
Float Shares70.35M
Fifty Two Week High31.41
Enterprise Value To Ebitda-13.61
Fifty Day Average22.29
Two Hundred Day Average22.54
Enterprise Value To Revenue23.77
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.